GlobalData, a leading data and analytics company, has found that the COVID-19 pandemic has led to temporarily increased drug sales for big bio/pharma companies in the first quarter (Q1) of 2020. This increase was due to people stockpiling in preparation for limited medical access during the lockdown.
GlobalData’s Pharma Intelligence Center Drug Sales and Forecast Database reveals that global sales in Q1 2020 for companies that were not developing a COVID-19 drug saw an 8% increase in sales when compared to the archived global sales forecast for the same time period. In contrast, companies that were developing a COVID-19 drug only saw a 3% increase.
For more information, click here.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.